Skip to main content
. Author manuscript; available in PMC: 2023 May 30.
Published in final edited form as: Urol Oncol. 2021 Nov 7;40(1):4.e1–4.e7. doi: 10.1016/j.urolonc.2021.09.007

Table 2.

Univariable analyses of clinical variables and biomarkers in predicting the probability of GG≥2 cancer on surgical pathology.

Predictors Univariable Analysis
OR (95% CI) p-value
Age 1.02 (0.95 – 1.10) 0.6
Abnormal DRE 1.88 (0.35 – 10.18) 0.5
Prior Negative Biopsy 1.17 (0.26 – 5.21) 0.8
Family History 0.83 (0.22–3.04) 0.8
PCPThg-rc 1.03 (0.93–1.13) 0.6
Number of positive cores 1.36 (0.94–1.97) 0.11
PSA 0.99 (0.75 – 1.30) 0.9
PSAD 1.07 (0.97 – 1.18) 0.15
PCA3 1.03 (1.01 – 1.06) 0.02
T2:ERG 1.00 (1.00 – 1.01) 0.2
MPS 1.07 (1.02 – 1.12) 0.004

OR: odds ratio; 95% CI: 95% confidence interval; DRE: digital rectal examination; PCPThg-rc: Prostate Cancer Prevention Trial high grade risk calculator; PSA: prostate-specific antigen; PSAD: PSA density; PCA3: Prostate Cancer Antigen 3; T2:ERG: TMPRSS2:ERG gene fusion; MPS: MyProstateScore.